The scientific program's plenary sessions cover: Novel therapies and international considerations in access and regulatory approval Economics of novel cellular therapies Transplantation and cell ...

While Monday’s trading session was a win for CERo shareholders, the stock’s year-to-date (YTD) performance paints a more complex picture. As of today, CERO is down by a staggering -98.59% YTD, which ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced members of the management team are scheduled to partic ...

The approval follows a heightened regulatory focus on CAR-T cell therapy safety this year. In April, the FDA mandated boxed ...

The presentation at SITC titled, ‘Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced ...

On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics, whose share rose more than 8% to 44.03 on the news.

The bottom line is that the key to better cancer outcomes is found in early detection. Most malignancies that usually affect ...

Like other CAR-T products, Aucatzyl still comes with an FDA boxed warning for CRS, neurotoxicity and secondary T-cell malignancies. A lack of REMS requirement could work to further support adoption by ...

Mass spectrometry and machine learning show promise for early cancer detection and prognosis by analyzing metabolic signatures.

ASTCT® and CIBMTR® Bring Leading Experts Together to Share Groundbreaking Advancements in Hematopoietic Cell Transplantation, Cellular Therapy and Gene Therapy.

Rigorous surveillance of children at high risk for developing myelodysplastic syndrome (MDS) is especially warranted, ...